Syntara Limited (ASX:SNT), a clinical-stage drug development company, has announced that the first participant has been dosed in the Phase 1a/b clinical trial for its topical pan-lysyl oxidase inhibitor SNT-9465, developed for the treatment of hypertrophic scars.
The trial, which commenced dosing at the Linear (Joondalup Clinical Trial Centre) in Perth, will initially assess the safety and tolerability of the drug in healthy participants.
The Phase 1a study will determine the optimal dose for complete lysyl oxidase inhibition and will be followed by an open-label Phase 1b extension designed to assess improvements in appearance and composition of hypertrophic scars after three months of daily treatment. The trial results, expected in the first half of 2026, are anticipated to support an FDA Investigational New Drug (IND) application, paving the way for a global development program with the potential to deliver the first approved pharmacological treatment for skin scarring.
Syntara CEO, Gary Phillips, said, “Our discussions with clinicians and global key opinion leaders in scar treatment have highlighted a significant unmet need for patients. Current standard of care includes costly laser therapy or painful steroid injections, requiring multiple treatments for only small incremental improvements. Daily topical treatment with SNT-9465 has the potential to provide profound patient benefits with a non-invasive treatment and without the need for repeat clinical visits.”
Approximately 100 million patients develop scars in the developed world each year as a result of elective operations and operations after trauma.